Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02632409
Registration number
NCT02632409
Ethics application status
Date submitted
14/12/2015
Date registered
16/12/2015
Date last updated
8/01/2024
Titles & IDs
Public title
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Query!
Scientific title
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
Query!
Secondary ID [1]
0
0
2014-003626-40
Query!
Secondary ID [2]
0
0
CA209-274
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CheckMate 274
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Various Advanced Cancer
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: Nivolumab - Nivolumab dose as specified
Placebo comparator: Placebo - Placebo dose as specified
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Disease Free Survival (DFS)
Query!
Assessment method [1]
0
0
The time between the date of randomization and the date of first documented recurrence (local urothelial tract, local non-urothelial tract or distant), or death due to any cause, whichever occurs first.
Query!
Timepoint [1]
0
0
approximately up to 48 months
Query!
Primary outcome [2]
0
0
Disease Free Survival (DFS) in PD-L1 Expression = 1% Population
Query!
Assessment method [2]
0
0
The time between the date of randomization and the date of first documented recurrence (local urothelial tract, local non-urothelial tract or distant), or death due to any cause, whichever occurs first.
Query!
Timepoint [2]
0
0
approximately up to 48 months
Query!
Secondary outcome [1]
0
0
Non-Urothelial Tract Recurrence Free Survival
Query!
Assessment method [1]
0
0
The time between the date of randomization and the date of first documented recurrence (local non-urothelial tract or distant), or death due to any cause, whichever occurs first.
Query!
Timepoint [1]
0
0
up to 53 months
Query!
Secondary outcome [2]
0
0
Non-Urothelial Tract Recurrence Free Survival in PD-L1 Expression = 1% Population
Query!
Assessment method [2]
0
0
The time between the date of randomization and the date of first documented recurrence (local non-urothelial tract or distant), or death due to any cause, whichever occurs first.
Query!
Timepoint [2]
0
0
up to 53 months
Query!
Secondary outcome [3]
0
0
Overall Survival
Query!
Assessment method [3]
0
0
the time from randomization to the date of death from any cause.
Query!
Timepoint [3]
0
0
on going
Query!
Secondary outcome [4]
0
0
Overall Survival in Participants With PD-L1 Expression = 1%
Query!
Assessment method [4]
0
0
the time from randomization to the date of death from any cause.
Query!
Timepoint [4]
0
0
on going
Query!
Secondary outcome [5]
0
0
Disease Specific Survival
Query!
Assessment method [5]
0
0
the time from randomization to the date of death due to disease (urothelial cancer).
Query!
Timepoint [5]
0
0
on going
Query!
Secondary outcome [6]
0
0
Disease Specific Survival in Participants With PD-L1 Expression = 1%
Query!
Assessment method [6]
0
0
the time from randomization to the date of death due to disease (urothelial cancer).
Query!
Timepoint [6]
0
0
on going
Query!
Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
* Must have had invasive urothelial cancer at high risk of recurrence originating in the bladder, ureter, or renal pelvis
* Must have had radical surgical resection (e.g. radical cystectomy), performed within the last 120 days
* Must have disease free status as determined by imaging within 4 weeks of dosing
* Tumor tissue must be provided for biomarker analysis
* Patients who have not received prior neoadjuvant cisplatin chemotherapy must be ineligible for or refuse cisplatin-based adjuvant chemotherapy
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Partial bladder or partial kidney removal (eg, partial cystectomy or partial nephrectomy)
* Secondary Treatment (eg, adjuvant systemic chemotherapy for bladder cancer) following surgical removal of bladder cancer
* Subjects with active, known or suspected autoimmune disease
* Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
* Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 day of study drug administration
* Positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/03/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
27/05/2027
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
709
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - 0048 - Liverpool
Query!
Recruitment hospital [2]
0
0
Local Institution - 0047 - St. Leonards
Query!
Recruitment hospital [3]
0
0
Local Institution - 0046 - Waratah
Query!
Recruitment hospital [4]
0
0
Local Institution - 0050 - Elizabeth Vale
Query!
Recruitment hospital [5]
0
0
Local Institution - 0184 - Frankston
Query!
Recruitment hospital [6]
0
0
Local Institution - 0175 - Perth
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [3]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [4]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [5]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [6]
0
0
6150 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alaska
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nebraska
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nevada
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Buenos Aires
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
RIO Negro
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Tucuman
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Linz
Query!
Country [24]
0
0
Austria
Query!
State/province [24]
0
0
Salzburg
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Vienna
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Wien
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Hasselt
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Liege
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
RIO Grande DO SUL
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Sao Paulo
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
SAO Paulo
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Rio De Janeiro
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
São Paulo
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Alberta
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Montreal
Query!
Country [37]
0
0
Chile
Query!
State/province [37]
0
0
Metropolitana
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
Valparaiso
Query!
Country [39]
0
0
Chile
Query!
State/province [39]
0
0
Temuco
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Beijing
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Chongqing
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Fujian
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Guangdong
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Guangxi
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Hubei
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Jiangsu
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Jiangxi
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Shan3xi
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Shandong
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Shanghai
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Sichuan
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Zhejiang
Query!
Country [53]
0
0
Colombia
Query!
State/province [53]
0
0
Bogota
Query!
Country [54]
0
0
Colombia
Query!
State/province [54]
0
0
Floridablanca
Query!
Country [55]
0
0
Colombia
Query!
State/province [55]
0
0
Medellin
Query!
Country [56]
0
0
Denmark
Query!
State/province [56]
0
0
Aalborg
Query!
Country [57]
0
0
Denmark
Query!
State/province [57]
0
0
Aarhus N
Query!
Country [58]
0
0
Denmark
Query!
State/province [58]
0
0
Copenhagen
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Clermont-ferrand
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
La Roche-sur-Yon
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Marseille Cedex 9
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Paris
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Strasbourg
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Suresnes
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Villejuif
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Chemnitz
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Essen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Greifswald
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Hamburg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Heidelberg
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Jena
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Marburg
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Muenster
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Munich
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Nuernberg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Regensburg
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Stuttgart
Query!
Country [78]
0
0
Greece
Query!
State/province [78]
0
0
Athens
Query!
Country [79]
0
0
Greece
Query!
State/province [79]
0
0
Thessaloniki
Query!
Country [80]
0
0
Ireland
Query!
State/province [80]
0
0
Cork
Query!
Country [81]
0
0
Ireland
Query!
State/province [81]
0
0
Dublin
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Haifa
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Jerusalem
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Ramat Gan
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Zerifin
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Arezzo
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Bergamo
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Milano
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Pisa
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Reggio Emilia
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Roma
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Siena
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Akita
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Aomori
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Fukuoka
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Hokkaido
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Ibaraki
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Nagasaki
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Niigata
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Okayama
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Osaka
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Shizuoka
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Tokyo
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Chiba
Query!
Country [105]
0
0
Korea, Republic of
Query!
State/province [105]
0
0
Seongnam-si
Query!
Country [106]
0
0
Korea, Republic of
Query!
State/province [106]
0
0
Seoul
Query!
Country [107]
0
0
Mexico
Query!
State/province [107]
0
0
Distrito Federal
Query!
Country [108]
0
0
Mexico
Query!
State/province [108]
0
0
Jalisco
Query!
Country [109]
0
0
Mexico
Query!
State/province [109]
0
0
Nuevo Leon
Query!
Country [110]
0
0
Netherlands
Query!
State/province [110]
0
0
Amsterdam
Query!
Country [111]
0
0
Netherlands
Query!
State/province [111]
0
0
Maastrict
Query!
Country [112]
0
0
Netherlands
Query!
State/province [112]
0
0
Nijmegen
Query!
Country [113]
0
0
Peru
Query!
State/province [113]
0
0
Lima
Query!
Country [114]
0
0
Poland
Query!
State/province [114]
0
0
Gdansk
Query!
Country [115]
0
0
Poland
Query!
State/province [115]
0
0
Lodz
Query!
Country [116]
0
0
Poland
Query!
State/province [116]
0
0
Warsaw
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Wroclaw
Query!
Country [118]
0
0
Romania
Query!
State/province [118]
0
0
Bucuresti
Query!
Country [119]
0
0
Romania
Query!
State/province [119]
0
0
Craiova
Query!
Country [120]
0
0
Romania
Query!
State/province [120]
0
0
Floresti
Query!
Country [121]
0
0
Romania
Query!
State/province [121]
0
0
Timisoara, Timis
Query!
Country [122]
0
0
Russian Federation
Query!
State/province [122]
0
0
Moscow
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Saint-Petersburg
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Badalona-barcelona
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Barcelona
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Madrid
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Santander
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Sevilla
Query!
Country [129]
0
0
Sweden
Query!
State/province [129]
0
0
Lund
Query!
Country [130]
0
0
Switzerland
Query!
State/province [130]
0
0
Basel
Query!
Country [131]
0
0
Switzerland
Query!
State/province [131]
0
0
Zuerich
Query!
Country [132]
0
0
Taiwan
Query!
State/province [132]
0
0
Kaohsiung
Query!
Country [133]
0
0
Taiwan
Query!
State/province [133]
0
0
Taichung
Query!
Country [134]
0
0
Taiwan
Query!
State/province [134]
0
0
Taipei
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Greater Manchester
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Midlothian
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Surrey
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
Yorkshire
Query!
Country [139]
0
0
United Kingdom
Query!
State/province [139]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Ono Pharmaceutical Co. Ltd
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02632409
Query!
Trial related presentations / publications
Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442. Erratum In: N Engl J Med. 2021 Aug 26;385(9):864. doi: 10.1056/NEJMx210012.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/09/NCT02632409/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/09/NCT02632409/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02632409
Download to PDF